Skip to content

Structural brain changes in bipolar disorder

Structural brain changes in bipolar disorder - Structural brain changes in bipolar disorder

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON38291
Enrollment
600
Registered
2011-06-07
Start date
2011-06-16
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bipolar disorder manic depressive disorder

Interventions

None listed

Sponsors

Universitair Medisch Centrum Utrecht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients with bipolar disorder - A diagnosis of BD-I according to the DSM IV, with at least one clinical intervention for mania (DSM-IV criteria) - No history of Cognitive Disorder (DSM-IV criteria) - Age >= 18 years - Dutch ancestry (at least three of the four grandparents from the Netherlands);Healthy controls - Age >= 18 years - Dutch ancestry (at least three of the four grandparents from the Netherlands) - No history of bipolar disorder, schizophrenia or other psychotic disorder (DSM-IV criteria) - No first degree relative with a history of bipolar disorder, schizophrenia or other psychotic disorders (DSM-IV criteria), on the basis of a FIGS interview

Exclusion criteria

Exclusion criteria: - Premorbid IQ

Design outcomes

Primary

MeasureTime frame
The main studyparameter is structural abnormalities in the brain of bipolar patients, compared to unrelated healthy controls. These structural differences will be measured by; - Brain volume (sMRI) and density (voxelbased morphometry) - Fractional anisotropy and magnetisation transfer ratio

Secondary

MeasureTime frame
The secondary parameter is data that associates the structural data with genetic data. Furthermore, we will also study baseline values or parameters which might intervene with the main study parameter, like age, gender, years of education, symptoms, level of functioning, medication intake and life events. We are mainly interested in the effect op medication on the bipolar brain.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)